Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/127337
DC FieldValueLanguage
dc.contributor.authorNunes, Ten_US
dc.contributor.authorBarreiro-de Acosta, Men_US
dc.contributor.authorNos, Pen_US
dc.contributor.authorMarin-Jiménez, Ien_US
dc.contributor.authorBermejo, Fen_US
dc.contributor.authorCeballos Santos, Daniel Sebastiánen_US
dc.contributor.authorIglesias, Een_US
dc.contributor.authorGomez-Senent, Sen_US
dc.contributor.authorTorres, Yen_US
dc.contributor.authorPonferrada, Aen_US
dc.contributor.authorArevalo, JAen_US
dc.contributor.authorHernandez, Ven_US
dc.contributor.authorCalvet, Xen_US
dc.contributor.authorGinard, Den_US
dc.contributor.authorMonfort, Den_US
dc.contributor.authorChaparro, Men_US
dc.contributor.authorManceñido, Nen_US
dc.contributor.authorDomínguez-Antonaya, Men_US
dc.contributor.authorVillalón, Cen_US
dc.contributor.authorPerez-Calle, JLen_US
dc.contributor.authorMuñoz, Cen_US
dc.contributor.authorNuñez, Hen_US
dc.contributor.authorCarpio, Den_US
dc.contributor.authorAramendiz, Ren_US
dc.contributor.authorBujanda, Len_US
dc.contributor.authorEstrada-Oncins, Sen_US
dc.contributor.authorHermida, Cen_US
dc.contributor.authorBarrio, Jen_US
dc.contributor.authorCasis, MBen_US
dc.contributor.authorDueñas-Sadornil, MCen_US
dc.contributor.authorFernández, Len_US
dc.contributor.authorCalvo-Cenizo, MMen_US
dc.contributor.authorBotella, Ben_US
dc.contributor.authorde Francisco, Ren_US
dc.contributor.authorAyala, Een_US
dc.contributor.authorSans, Men_US
dc.date.accessioned2023-10-20T13:17:36Z-
dc.date.available2023-10-20T13:17:36Z-
dc.date.issued2010en_US
dc.identifier.issn1873-9946en_US
dc.identifier.urihttp://hdl.handle.net/10553/127337-
dc.description.abstractBackground: Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice. Methods: Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points and > 30%, and failure as lack of remission or response. Results: BDP dose was 5. mg/day in 88% of patients and mean treatment duration was 6.2. weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased from 4.9 ± 1.3 to 2.4 ± 2.3 (p. < 0.0001). Remission rate was higher in mild and moderate than in severe UC (p. < 0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p. < 0.06). Failure was less frequent in patients treated for > 4. weeks (p. < 0.02). Mild adverse events were reported in 7.6% of patients. Conclusion: BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4. weeks are most likely to benefit from this treatment. © 2010 European Crohn's and Colitis Organisation.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Crohn's and Colitisen_US
dc.sourceJournal of Crohn's and Colitis [1873-9946], v. 4(6), pp. 629-636 (Diciembre 2010)en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject3208 Farmacodinámicaen_US
dc.subject.otherBeclometasone dipropionateen_US
dc.subject.otherSteroidsen_US
dc.subject.otherUlcerative colitisen_US
dc.titleUsefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Studyen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.crohns.2010.07.003en_US
dc.identifier.scopus2-s2.0-78649514108-
dc.identifier.isiWOS:000286086800003-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.description.lastpage636en_US
dc.identifier.issue6-
dc.description.firstpage629en_US
dc.relation.volume4en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages8en_US
dc.utils.revisionen_US
dc.date.coverdateDiciembre 2010en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr2,628
dc.description.jcrqQ2
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0003-2384-4524-
crisitem.author.fullNameCeballos Santos, Daniel Sebastián-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

26
checked on Jun 9, 2024

WEB OF SCIENCETM
Citations

20
checked on Jun 9, 2024

Page view(s)

36
checked on May 18, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.